DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Triheptanoin is an investigational drug.
There have been 32 clinical trials for Triheptanoin. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Syndrome, Carbohydrate Metabolism, Inborn Errors, and Metabolic Diseases. The leading clinical trial sponsors are Ultragenyx Pharmaceutical Inc, Institut National de la Santé Et de la Recherche Médicale, France, and University of Texas Southwestern Medical Center.
Recent Clinical Trials for Triheptanoin
|Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I||Ultragenyx Pharmaceutical Inc||Early Phase 1|
|Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I||Areeg El-Gharbawy||Early Phase 1|
|A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)||Ultragenyx Pharmaceutical Inc||Phase 1/Phase 2|